# Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

> **NCT00201682** · PHASE1,PHASE2 · COMPLETED · sponsor: **John Byrd** · enrollment: 36 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Etanercept
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00201682
- **Lead sponsor:** John Byrd
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2006-08
- **Final completion:** 2009-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00201682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00201682, "Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00201682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*